The glucagon-like peptide 1 market size has grown strongly in recent years. It will grow from $20.88 billion in 2024 to $22.37 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%.

The Business Research Company The Business Research Company's Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Global Market Report. Tuesday, 02 January 2024 12:17 GMT.

In 2021, the global glucagon-like peptide 1 (GLP-1) market was valued at US$16.53 billion, and is probable to reach US$24.10 billion by 2027. The glucagon-like peptide 1 (GLP-1) market is ...

Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...

However, the current understanding of glucagon-like peptide-1 actions in renal pathways is inadequate. In rodent and human kidneys, GLP-1 receptors are present in vascular smooth muscles rather ...

Glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors are associated with additional effects beyond prolonging the effect of incretins. Laurie Baggio, PhD ...

Addex Scientists Discover Glucagon-like-peptide-1 (GLP-1) Induced Interaction Between GLP-1 and Gastric Inhibitory Peptide (GIP) Receptors Mon Nov 28, 2011 1:02am EST Addex Pharmaceuticals / Addex ...

Novel Glucagon like peptide-1 (GLP-1) drugs designed for type II diabetes. Hefei Institutes of Physical Science, Chinese Academy of Sciences . Journal Pharmaceuticals DOI 10.3390/ph15060740.

About The Article: This Viewpoint discusses the health benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs); summarizes the clinical, policy, and equity implications of GLP-1 RA ...

A glucagon-like peptide 1 (GLP-1)–receptor autoradiograph shows total binding of iodine-125–labeled GLP-1(7-36) amide in tumor tissue (Panel D); an autoradiograph with nonspecific binding is ...